Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7251 results

Sort By:

Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

Study ID: NCT03114462
Start Date: 2017-08-09
End Date: 2027-06-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

11

Intervention / Treatment

Stereotactic Hypofractionated Radioablation

Questionnaires

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

Study ID: NCT03104491
Start Date: 2017-07-31
End Date: 2027-05
Study Type

Interventional

Study Phase

Phase2

No. of Participants

44

Intervention / Treatment

Inotuzumab Ozogamicin

Sponsor

Leland Metheny

Source: clinicaltrials.gov

Share:
Add to list

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Study ID: NCT03520491
Start Date: 2018-04-25
End Date: 2026-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

45

Intervention / Treatment

Nivolumab

Ipilimumab

Radical cystectomy

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment

Study ID: NCT06217094
Start Date: 2025-06
End Date: 2029-09
Study Type

Interventional

Study Phase

Phase1

No. of Participants

18

Intervention / Treatment

NP-101 (3 g)

NP-101 (4.8 g)

NP-101 (6 g)

Sponsor

University of Florida

Source: clinicaltrials.gov

Share:
Add to list

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Study ID: NCT03914794
Start Date: 2020-10-02
End Date: 2027-05
Study Type

Interventional

Study Phase

Phase2

No. of Participants

43

Intervention / Treatment

Pemigatinibib

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Source: clinicaltrials.gov

Share:
Add to list

Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis

Study ID: NCT03073694
Start Date: 2017-07-14
End Date: 2025-07
Study Type

Interventional

Study Phase

Phase2

No. of Participants

100

Intervention / Treatment

Mitomycin c

Melphalan

Sponsor

University of Kansas Medical Center

Source: clinicaltrials.gov

Share:
Add to list

MRI Screening in Men at High Risk of Developing Prostate Cancer

Study ID: NCT05608694
Start Date: 2022-03-02
End Date: 2039-03-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

250

Intervention / Treatment

Prostate MRI

Sponsor

University of Chicago

Source: clinicaltrials.gov

Share:
Add to list

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Study ID: NCT04550494
Start Date: 2021-04-26
End Date: 2026-12-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

36

Intervention / Treatment

Biopsy Procedure

Biospecimen Collection

Computed Tomography

Magnetic Resonance Imaging

Carcolor

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Study ID: NCT04147494
Start Date: 2019-11-05
End Date: 2031-10-17
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

30

Intervention / Treatment

Computed Tomography

Gallium Ga 68 FAPi-46

Gallium Ga 68-labeled PSMA-11

Positron Emission Tomography

18F-FDG

Sponsor

Jonsson Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Study ID: NCT05604560
Start Date: 2023-11-08
End Date: 2026-09
Study Type

Interventional

Study Phase

Phase2

No. of Participants

25

Intervention / Treatment

Tiskelizumab

SX-682

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Source: clinicaltrials.gov

Share:
Add to list